Clinical Trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly. The purpose of this study is to investigate any side effects that may happen with CTX001, how CTX001 is absorbed by and processed in the body, and how CTX001 affects iron levels in the blood when administered with or without iron and/or food.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-13
Trial Details
NCT Number NCT07577817
Lead Sponsor Cajal Therapeutics Inc.
Conditions Anemia, Iron Deficiencies, Chronic Kidney Disease
Enrollment 72 participants
Start Date 2026-06
Primary Completion 2026-10 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-12